SCHEMBL19249105

SCHEMBL19249105

CC(C)(C)OC(=O)NCc1cc(=O)c2ccccc2[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSV O60911 1/20 0.46
▸ CTSL P07711 1/20 0.46
▸ CYP1A2 P05177 3/20 0.46
▸ MTNR1A P48039 2/20 0.45
▸ MTNR1B P49286 2/20 0.45
▸ KDM4A O75164 1/20 0.45
▸ BCHE P06276 1/20 0.45
▸ KDM4E B2RXH2 2/20 0.43
▸ GAA P10253 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ GRIN2D O15399 1/20 0.43
▸ GRIN3B O60391 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ GLA P06280 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ AHR P35869 1/20 0.43
▸ CHRNA7 P36544 1/20 0.43
▸ KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19249202 0.86 GABRA1 (0.48) MTNR1AMTNR1BKDM4ABCHEGRIN2D
SCHEMBL19248970 0.84 LMNA (0.46) CYP1A2MTNR1AMTNR1BKDM4AMEN1
SCHEMBL25677972 0.83 KDM4A (0.54) CYP1A2MTNR1AMTNR1BKDM4ABCHE
SCHEMBL30469092 0.83 KDM4A (0.54) CYP1A2MTNR1AMTNR1BKDM4ABCHE
SCHEMBL19248869 0.82 GABRA1 (0.48) MTNR1AMTNR1BKDM4AGRIN2DGRIN3B
SCHEMBL9177217 0.81 L3MBTL1 (0.42) CTSVCTSLKDM4AKDM4EGAA
SCHEMBL19211138 0.80 KDM4E (0.54) CTSVCTSLCYP1A2MTNR1AMTNR1B
SCHEMBL16808752 0.79 MTNR1A (0.47) CTSLCYP1A2MTNR1AMTNR1BKDM4A
SCHEMBL19248971 0.78 GABRA1 (0.52) CYP1A2MTNR1AMTNR1BGRIN2DGRIN3B
SCHEMBL19249203 0.78 P2RY14 (0.43) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11058676-B2 Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof PHARMAKEA, INC. (US) 2021-07-13 — — US disclosed
EP-3414229-B1 QUINOLINONE LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA INC (US) 2021-06-16 — — EP disclosed
WO-2017139274-A1 QUINOLINONE LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. (US) 2017-08-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11058676-B2 Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof LOXL2, LOXL1, LOX CTSV 70/4885CTSL 80/4885CYP1A2 177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback